TOFACITINIB CITRATE ( DrugBank: Tofacitinib )


5 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis74
49Systemic lupus erythematosus1
97Ulcerative colitis28
107Juvenile idiopathic arthritis16
271Ankylosing spondylitis14

46. Malignant rheumatoid arthritis


Clinical trials : 4,356Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 993Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 2,630Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

107. Juvenile idiopathic arthritis


Clinical trials : 447Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 574Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries